Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up of subjects treated with enadenotucirev
2016-004777-40Phase 2Completed
- Sponsor
- Akamis Bio
- Start
- Jan 2017
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of enadenotucirev in cancer, breast cancer, ovarian cancer and 2 more, sponsored by Akamis Bio. Primary endpoint: Time to death. Started Jan 2017; status: completed.
02
Drugs
enadenotucirev
03
Conditions
cancerbreast cancerovarian cancercolorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2016-004777-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004777-40.